Taskinen, Marja-Riitta

Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus

Yki-Järvinen, H., Kauppila, M., Kujansuu, E., Lahti, J., Marjanen, T., Niskanen, L., Rajala, S., Ryysy, L., Salo, S., Seppälä, P., et al. (1992) · New England Journal of Medicine

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 324

Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM.

Malmström, R., Packard, C. J., Caslake, M., Bedford, D., Stewart, P., Yki-Järvinen, H., Shepherd, J., & Taskinen, M.-R. (1997) · Diabetologia

Lipid metabolism and disordersDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 319

Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia

Borén, J., Taskinen, M.-R., Björnson, E., & Packard, C. J. (2022) · Nature Reviews Cardiology

Lipid metabolism and disordersCholesterol and Lipid Metabolism

Cited by 315

Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: Results from the Diabetes Atherosclerosis Intervention Study (DAIS)

Ansquer, J.-C., Foucher, C., Rattier, S., Taskinen, M.-R., & Steiner, G. (2005) · American Journal of Kidney Diseases

Chronic Kidney Disease and DiabetesDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 264

Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes

Bunck, M. C., Cornér, A., Eliasson, B., Heine, R. J., Shaginian, R. M., Taskinen, M.-R., Smith, U., Yki-Järvinen, H., & Diamant, M. (2011) · Diabetes Care

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 240

Causes and consequences of hypertriglyceridemia

Packard, C. J., Boren, J., & Taskinen, M.-R. (2020) · Frontiers in Endocrinology

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 239

Serum saturated fatty acids containing triacylglycerols are better markers of insulin resistance than total serum triacylglycerol concentrations

Kotronen, A., Velagapudi, V. R., Yetukuri, L., Westerbacka, J., Bergholm, R., Ekroos, K., Makkonen, J., Taskinen, M.-R., Orešič, M., & Yki-Järvinen, H. (2009) · Diabetologia

Diabetes, Cardiovascular Risks, and LipoproteinsLipid metabolism and disorders

Cited by 198

The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans

Borén, J., Packard, C. J., & Taskinen, M.-R. (2020) · Frontiers in Endocrinology

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 196

ESC/EAS Guidelines for the management of dyslipidaemias

Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 192

Triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease: a UK Biobank study

Björnson, E., Adiels, M., Taskinen, M.-R., Burgess, S., Rawshani, A., Borén, J., & Packard, C. J. (2023) · European Heart Journal

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 183

Postprandial hypertriglyceridemia as a coronary risk factor

Borén, J., Matikainen, N., Adiels, M., & Taskinen, M.-R. (2014) · Clinica Chimica Acta

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 182

Exenatide Affects Circulating Cardiovascular Risk Biomarkers Independently of Changes in Body Composition

Bunck, M. C., Diamant, M., Eliasson, B., Cornér, A., Shaginian, R. M., Heine, R. J., Taskinen, M.-R., Yki-Järvinen, H., & Smith, U. (2010) · Diabetes Care

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 161

Dual metabolic defects are required to produce hypertriglyceridemia in obese subjects

Taskinen, M.-R., Adiels, M., Westerbacka, J., Söderlund, S., Kahri, J., Lundbom, N., Lundbom, J., Hakkarainen, A., Olofsson, S.-O., Orho-Melander, M., et al. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology

Lipid metabolism and disordersDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 153

Long-term use of nicotine gum is associated with hyperinsulinemia and insulin resistance

Eliasson, B., Taskinen, M.-R., & Smith, U. (1996) · Circulation

Smoking Behavior and CessationDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 141

The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation

Fruchart, J.-C., Santos, R. D., Aguilar-Salinas, C., Aikawa, M., Al Rasadi, K., Amarenco, P., Barter, P. J., Ceska, R., Corsini, A., Després, J.-P., et al. (2019) · Cardiovascular Diabetology

Peroxisome Proliferator-Activated ReceptorsLipoproteins and Cardiovascular Health

Cited by 140

One-year treatment with exenatide vs. Insulin Glargine: Effects on postprandial glycemia, lipid profiles, and oxidative stress

Bunck, M. C., Cornér, A., Eliasson, B., Heine, R. J., Shaginian, R. M., Wu, Y., Yan, P., Smith, U., Yki-Järvinen, H., Diamant, M., et al. (2010) · Atherosclerosis

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 132

Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: a single-centre randomized controlled study

Matikainen, N., Söderlund, S., Björnson, E., Pietiläinen, K., Hakkarainen, A., Lundbom, N., Taskinen, M., & Borén, J. (2019) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 129

Alcohol-induced changes in serum lipoproteins and in their metabolism.

Taskinen, M.-R., Nikkilä, E. A., Välimäki, M., Sane, T., Kuusi, T., Kesäniemi, Y. A., & Ylikahri, R. (1987) · American Heart Journal

Alcohol Consumption and Health EffectsLipid metabolism and disorders

Cited by 122

PPARα: an emerging therapeutic target in diabetic microvascular damage

Hiukka, A., Maranghi, M., Matikainen, N., & Taskinen, M.-R. (2010) · Nature Reviews Endocrinology

Peroxisome Proliferator-Activated ReceptorsParaoxonase enzyme and polymorphisms

Cited by 103

Increased resting metabolic rates in obese subjects with non-insulin-dependent diabetes mellitus and the effect of sulfonylurea therapy

Bogardus, C., Taskinen, M.-R., Zawadzki, J., Lillioja, S., Mott, D., & Howard, B. V. (1986) · Diabetes

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Management and Research

Cited by 99

Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes

on behalf of the FIELD study investigators, Taskinen, M.-R., Barter, P. J., Ehnholm, C., Sullivan, D. R., Mann, K., Simes, J., Best, J. D., Hamwood, S., & Keech, A. C. (2010) · Diabetologia

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 94

Effects of Long-Term Fenofibrate Treatment on Markers of Renal Function in Type 2 Diabetes

Forsblom, C., Hiukka, A., Leinonen, E. S., Sundvall, J., Groop, P.-H., & Taskinen, M.-R. (2010) · Diabetes Care

Chronic Kidney Disease and DiabetesAcute Kidney Injury Research

Cited by 81

Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans

Borén, J., Adiels, M., Björnson, E., Matikainen, N., Söderlund, S., Rämö, J., Ståhlman, M., Ripatti, P., Ripatti, S., Palotie, A., et al. (2020) · JCI Insight

Lipid metabolism and disordersLiver Disease Diagnosis and Treatment

Cited by 81

Kinetic and Related Determinants of Plasma Triglyceride Concentration in Abdominal Obesity: Multicenter Tracer Kinetic Study

Borén, J., Watts, G. F., Adiels, M., Söderlund, S., Chan, D. C., Hakkarainen, A., Lundbom, J., Lundbom, N., Matikainen, N., Kahri, J., et al. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology

Lipid metabolism and disordersDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 72